RT Journal Article
T1 An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity.
A1 Doña, I
A1 Caubet, J C
A1 Brockow, K
A1 Doyle, M
A1 Moreno, E
A1 Terreehorst, I
A1 Torres, M J
K1 Anaphylaxis
K1 Betalactam
K1 Drug allergy
K1 Drug provocation test
K1 Exanthem
AB Adverse drug reactions include drug hypersensitivity reactions (DHRs), which can be immunologically mediated (allergy) or non-immunologically mediated. The high number of DHRs that are unconfirmed and often self-reported is a frequent problem in daily clinical practice, with considerable impact on future prescription choices and patient health. It is important to distinguish between hypersensitivity and non-hypersensitivity reactions by adopting a structured diagnostic approach to confirm or discard the suspected drug, not only to avoid life-threatening reactions, but also to reduce the frequent over-diagnosis of DHRs. Primary care physicians are often the first point of contact for the sufferer of a reaction, as such they have a key role in deciding whether to discard the diagnosis or send the patient for further investigation. In this review, we highlight the importance of diagnosing DHRs, analysing in detail the role of primary care physicians. We describe the common patterns of DHRs and signs of its progression, as well as the indications and contraindications for referring the patient to an allergist. The diagnostic process is described and the possible tests are discussed, which often depend on the drug involved and the type of DHR suspected. We also describe recommendations regarding the avoidance of medication suspected to have caused the reaction and the use of alternatives.
PB BioMed Central
SN 2045-7022
YR 2018
FD 2018-05-10
LK http://hdl.handle.net/10668/12466
UL http://hdl.handle.net/10668/12466
LA en
NO Doña I, Caubet JC, Brockow K, Doyle M, Moreno E, Terreehorst I, et al. An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity. Clin Transl Allergy. 2018 May 10;8:16
NO The present study has been supported in part by Institute of Health “CarlosIII” of the Ministry of Economy and Competitiveness [Grants cofundedby European Regional Development Fund (ERDF): PI15/01206, RIRAAFRD12/0013/0001 and ARADyAL RD16/0006/0001]. I Doña holds a Juan Rodesresearch contract (JR15/00036) from the Carlos III National Health Institute,Spanish Ministry of Economy and Competitiveness (Grants cofounded byEuropean Social Fund, ESF).
DS RISalud
RD Apr 18, 2025